English

Calmark receives order from Switzerland

Report this content
Calmark Sweden AB (publ) announces today that the Company has received an order from the distributor in Switzerland, LabForce AG, covering the Calmark Neo platform and bilirubin tests. The economic value of today's order is of minor importance, but it is important from a launch perspective.
As previously disclosed, an exclusive distributor agreement has been signed with the company LabForce regarding marketing and sales of the Calmark POC system in Switzerland. 
“I am happy for the order which shows that LabForce has started active sales work towards their customers, the clinics,” says Magdalena Tharaldsen, Director International Business Development at Calmark. “LabForce distributes more than 40 different brands in its home market and has a very good reputation. I look forward to deepening our cooperation.”

 
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
 

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 07-10-2021 12:11 CET.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.  

Subscribe

Documents & Links